CD274 and cancer: In the past 5 years, there has been significant advancement in the development of cancer immunotherapies with the introduction of immune checkpoint inhibitor (ICI) therapies such as anti-PD-(L)1 and anti-T-lymphocyte-associated protein 4 (CTLA-4) antibodies [17].